

Dated: April 17, 2012.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-10052 Filed 4-25-12; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application; Penick Corporation

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 1, 2012, Penick Corporation, 33 Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Cocaine (9041)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Ecgonine (9180)	II
Hydrocodone (9193)	II
Morphine (9300)	II
Oripavine (9330)	II
Thebaine (9333)	II
Oxymorphone (9652)	II

The company plans to manufacture the listed controlled substances as bulk controlled substance intermediates for distribution to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than June 25, 2012.

Dated: April 17, 2012.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-10040 Filed 4-25-12; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application; Cambrex Charles City, Inc.

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 30, 2011, Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Cocaine (9041)	II
Opium tincture (9630)	II

The company plans to manufacture the listed controlled substances in bulk for sale to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than June 25, 2012.

Dated: April 17, 2012.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-10059 Filed 4-25-12; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application; Cambrex Charles City, Inc.

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 30, 2011, Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Hydrocodone (9193)	II
Methadone (9250)	II

The company plans to manufacture the listed controlled substances in bulk for sale to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than June 25, 2012.

Dated: April 17, 2012.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-10057 Filed 4-25-12; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application Rhodes Technologies

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 24, 2012, Rhodes Technologies, 498 Washington Street, Coventry, Rhode Island 02816, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Tetrahydrocannabinols (7370)	I
Methylphenidate (1724)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Hydrocodone (9193)	II
Oripavine (9330)	II
Thebaine (9333)	II
Oxymorphone (9652)	II
Noroxymorphone (9668)	II
Fentanyl (9801)	II

The company plans to manufacture the listed controlled substances in bulk for conversion and sale to dosage form manufacturers.

Any other such applicant, and any person who is presently registered with

DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than June 25, 2012.

Dated: April 17, 2012.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-10054 Filed 4-25-12; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration; Cerilliant Corporation

By Notice dated January 5, 2012, and published in the **Federal Register** on January 17, 2012, 77 FR 2321, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Cathinone (1235)	I
Methcathinone (1237)	I
N-Ethylamphetamine (1475)	I
N,N-Dimethylamphetamine (1480)	I
Aminorex (1585)	I
4-Methylaminorex (cis isomer) (1590)	I
Gamma-Hydroxybutyric acid (2010)	I
Methaqualone (2565)	I
1-Pentyl-3-(1-naphthoyl)indole (7118)	I
1-Butyl-3-(1-naphthoyl)indole (7173)	I
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl) Indole (7200)	I
Alpha-ethyltryptamine (7249)	I
5-(1,1-Dimethylheptyl)-2-[[1R,3S)-3-hydroxycyclohexyl]-phenol (7297)	I
5-(1,1-Dimethyloctyl)-2-[[1R,3S)-3-hydroxycyclohexyl]-phenol (7298)	I
Lysergic acid diethylamide (7315)	I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348)	I
Marihuana (7360)	I
Tetrahydrocannabinols (7370)	I
Mescaline (7381)	I

Drug	Schedule	Drug	Schedule
3,4,5-Trimethoxyamphetamine (7390)	I	Beta-hydroxy-3-methylfentanyl (9831)	I
4-Bromo-2,5-dimethoxyamphetamine (7391)	I	Alpha-Methylthiofentanyl (9832)	I
4-Bromo-2,5-dimethoxyphenethylamine (7392)	I	3-Methylthiofentanyl (9833)	I
4-Methyl-2,5-dimethoxyamphetamine (7395)	I	Thiofentanyl (9835)	I
2,5-Dimethoxyamphetamine (7396)	I	Amphetamine (1100)	II
2,5-Dimethoxy-4-ethylamphetamine (7399)	I	Methamphetamine (1105)	II
3,4-Methylenedioxyamphetamine (7400)	I	Lisdexamfetamine (1205)	II
5-Methoxy-3,4-methylenedioxyamphetamine (7401)	I	Phenmetrazine (1631)	II
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)	I	Methylphenidate (1724)	II
3,4-Methylenedioxy-N-ethylamphetamine (7404)	I	Amobarbital (2125)	II
3,4-Methylenedioxymethamphetamine (7405)	I	Pentobarbital (2270)	II
4-Methoxyamphetamine (7411)	I	Secobarbital (2315)	II
5-Methoxy-N,N-dimethyltryptamine (7431)	I	Glutethimide (2550)	II
Alpha-methyltryptamine (7432)	I	Nabilone (7379)	II
Bufotenine (7433)	I	1-Phenylcyclohexylamine (7460)	II
Diethyltryptamine (7434)	I	Phencyclidine (7471)	II
Dimethyltryptamine (7435)	I	1-Piperidinocyclohexanecarbonitrile (8603)	II
Psilocybin (7437)	I	Alphaprodine (9010)	II
Psilocyn (7438)	I	Cocaine (9041)	II
5-Methoxy-N,N-diisopropyltryptamine (7439)	I	Codeine (9050)	II
N-Benzylpiperazine (7493)	I	Dihydrocodeine (9120)	II
Acetyldihydrocodeine (9051)	I	Oxycodone (9143)	II
Benzylmorphine (9052)	I	Hydromorphone (9150)	II
Codeine-N-oxide (9053)	I	Diphenoxylate (9170)	II
Dihydromorphine (9145)	I	Benzoylcegonine (9180)	II
Heroin (9200)	I	Ethylmorphine (9190)	II
Hydromorphenol (9301)	I	Hydrocodone (9193)	II
Methyldihydromorphine (9304)	I	Levomethorphan (9210)	II
Morphine-N-oxide (9307)	I	Levorphanol (9220)	II
Normorphine (9313)	I	Isomethadone (9226)	II
Pholcodine (9314)	I	Meperidine (9230)	II
Acetylmetadol (9601)	I	Meperidine intermediate-A (9232)	II
Allylprodine (9602)	I	Meperidine intermediate-B (9233)	II
Alphacetylmethadol except levoracemate (9603)	I	Meperidine intermediate-C (9234)	II
Alphameprodine (9604)	I	Methadone (9250)	II
Alphamethadol (9605)	I	Methadone intermediate (9254)	II
Betacetylmethadol (9607)	I	Dextropropoxyphene, bulk (non-dosage forms) (9273)	II
Betameprodine (9608)	I	Morphine (9300)	II
Betamethadol (9609)	I	Thebaine (9333)	II
Betaprodine (9611)	I	Levo-alphaacetylmethadol (9648)	II
Hydroxypethidine (9627)	I	Oxymorphone (9652)	II
Noracymethadol (9633)	I	Noroxymorphone (9668)	II
Norlevorphanol (9634)	I	Racemethorphan (9732)	II
Normethadone (9635)	I	Alfentanil (9737)	II
Trimperidine (9646)	I	Sufentanil (9740)	II
Phenomorphan (9647)	I	Tapentadol (9780)	II
1-Methyl-4-phenyl-4-propionoxypiperidine (9661)	I	Fentanyl (9801)	II
Tilidine (9750)	I		
Para-Fluorofentanyl (9812)	I		
3-Methylfentanyl (9813)	I		
Alpha-Methylfentanyl (9814)	I		
Acetyl-alpha-methylfentanyl (9815)	I		
Beta-hydroxyfentanyl (9830)	I		

The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Cerilliant Corporation to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cerilliant Corporation to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and